Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin for metastatic urothelial cancer

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 1, 2001, Pages 88-93

  Fukui, I ^a   Yonese, J ^a   Tsukamoto, T ^a   Yoshida, T ^a   Kim, T ^a   Tohma, T ^a   Ishiwata, D ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

IFEP chemotherapy; Metastatic urothelial cancer; Treatment results

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER DYSFUNCTION; LYMPH NODE METASTASIS; MALE; METASTASIS; PRIORITY JOURNAL; SALVAGE THERAPY; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; UROGENITAL TRACT TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CISPLATIN; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 0034916859     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100320     Document Type: Article

References (19)

1. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder
2. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma
3. Single-drug chemotherapy with 5-FU and Adriamycin in metastatic bladder carcinoma
4. Combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cis-platin (IFEP) for metastatic urothelial cancer
5. Chemotherapy in invasive carcinoma of the bladder. A review of phase II trials in Egypt
6. Phase II trial of combination VP16 and cis-platinum in advanced measurable bladder cancer
7. Cisplatin, methotrexate and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: A Northern California Oncology Group Study
8. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer
9. Nonparametric estimation from incomplete observations
10. A randomized trial of chemotherapy for advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin
11. Chemotherapy for advanced bladder cancer
12. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma; a cooperative group study
13. cis-dichlorodiammineplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice
14. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse
15. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience
16. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies
17. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer
18. Phase II study of etoposide for carcinoma of the bladder: The Southeastern Cancer Study Group experience
19. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma